The May 10 issue of The Cancer Letter details a recent publication explaining the investigation of a new AI tool that may be able to match cancer drugs more precisely to patients.
The Cancer Letter—a news organization and weekly publication based in Washington, D.C., that focuses on cancer research and clinical care—included an article in its May 10 issue about a partnership between scientists at Sanford Burnham Prebys and the National Cancer Institute (NCI).
Authored by Sanju Sinha, PhD, assistant professor in the Cancer Molecular Therapeutics Program at Sanford Burnham Prebys, and the NCI’s Eytan Ruppin, MD, PhD, the “Trials & Tribulations” feature describes a first-of-its-kind computational tool to systematically predict patient response to cancer drugs at single-cell resolution. The study regarding this new tool was published on April 18, 2024, in the journal Nature Cancer.
The Cancer Letter was founded in 1973 and focuses its coverage on the development of cancer therapies, drug regulation, legislation, cancer research funding, health care finance and public health.